What is the recommended work‑up and treatment for a patient presenting with hematuria?

Management of Hematuria

Immediate Diagnostic Confirmation

Before initiating any workup, confirm true hematuria with microscopic urinalysis showing ≥3 red blood cells per high-power field (RBC/HPF) on a properly collected clean-catch midstream specimen. 1, 2 Dipstick testing alone has only 65-99% specificity and produces false positives from myoglobin, hemoglobin, menstrual blood, or contaminants. 1, 2

Critical First Distinction: Gross vs. Microscopic

• Gross (visible) hematuria carries a 30-40% malignancy risk and requires urgent urologic referral within 24-48 hours for cystoscopy and upper tract imaging, even if self-limited. 1, 2, 3
• Microscopic hematuria requires risk stratification before determining the extent of evaluation. 1, 2

Risk Stratification for Microscopic Hematuria

The American Urological Association stratifies patients into risk categories that determine the intensity of workup: 2

High-Risk Features (Mandate Full Urologic Evaluation: Cystoscopy + CT Urography)

• Age ≥60 years (both men and women) 2
• Smoking history >30 pack-years 2
• Any prior episode of gross hematuria, even if self-limited 2
• Occupational exposure to benzenes, aromatic amines, or industrial chemicals/dyes 1, 2
• Irritative voiding symptoms (urgency, frequency, dysuria) without documented infection 2, 4
• Degree of hematuria >25 RBC/HPF 2

Intermediate-Risk Features (Shared Decision-Making)

• Men aged 40-59 years or women aged 50-59 years 2
• Smoking history 10-30 pack-years 2
• Hematuria 11-25 RBC/HPF 2

Low-Risk Features (May Defer Extensive Imaging)

• Men <40 years or women <50 years 2
• Never smoker or <10 pack-years 2
• Hematuria 3-10 RBC/HPF 2

Distinguishing Glomerular from Urologic Sources

This distinction determines whether nephrology referral is needed in addition to urologic evaluation: 2

Glomerular Indicators (Prompt Nephrology Referral)

• 80% dysmorphic RBCs on urinary sediment examination 2, 5

• Presence of red blood cell casts (pathognomonic for glomerular disease) 2, 5
• Protein-to-creatinine ratio >0.5 g/g 2, 3
• Elevated serum creatinine or declining eGFR 2
• Tea-colored or cola-colored urine 2, 3
• Concurrent hypertension with hematuria and proteinuria 2

Non-Glomerular Indicators (Focus on Urologic Evaluation)

• Predominantly normal-shaped RBCs with minimal proteinuria 2
• Absence of RBC casts or dysmorphic RBCs 2
• Normal renal function 2

Even when glomerular features are present, complete the full urologic workup because malignancy can coexist with medical renal disease. 2, 3

Complete Urologic Evaluation

Upper Tract Imaging

Multiphasic CT urography (unenhanced, nephrographic, and excretory phases) is the preferred imaging modality, demonstrating 96% sensitivity and 99% specificity for renal cell carcinoma, transitional cell carcinoma, and urolithiasis. 2, 4, 3 This single study evaluates kidneys, collecting systems, ureters, and bladder comprehensively. 2

• When CT is contraindicated (severe renal insufficiency or contrast allergy), use MR urography or renal ultrasound with retrograde pyelography as alternatives. 1, 2
• Renal ultrasound alone is insufficient for comprehensive upper tract evaluation and cannot reliably detect small urothelial carcinomas or evaluate the ureters. 2, 5

Lower Tract Evaluation

Flexible cystoscopy is mandatory for all patients with gross hematuria and for microscopic hematuria patients ≥40 years or with any high-risk features. 1, 2, 4 Bladder cancer accounts for 30-40% of gross hematuria cases and 2.6-4% of microscopic hematuria cases, and imaging alone cannot exclude it. 2, 3

• Flexible cystoscopy is preferred over rigid cystoscopy because it causes less pain while providing equivalent or superior diagnostic accuracy. 1, 2, 3

Adjunctive Testing

• Voided urine cytology should be obtained in high-risk patients (age >60 years, smoking >30 pack-years, occupational exposures) to detect high-grade urothelial carcinomas and carcinoma in situ. 2, 3
• Serum creatinine and BUN to assess renal function. 2, 4
• Urine culture before initiating antibiotics if infection is suspected. 2, 4

Critical Management Pitfalls to Avoid

• Never dismiss hematuria in patients on anticoagulation or antiplatelet therapy—these medications unmask underlying pathology but do not cause hematuria. 1, 2, 4, 3 Evaluation must proceed regardless of medication use.
• Never ignore gross hematuria even if self-limited—30-40% harbor malignancy. 1, 2, 3
• Never rely solely on dipstick testing—microscopic confirmation of ≥3 RBC/HPF is required before initiating workup. 1, 2
• Never delay evaluation in patients ≥35-40 years with confirmed hematuria, even if a benign cause is suspected. 2, 5
• Do not attribute hematuria to benign prostatic hyperplasia without complete evaluation—malignancy can coexist. 4

Special Clinical Scenarios

Hematuria with Urinary Tract Infection

• Obtain urine culture before antibiotics. 2, 4
• If microscopic hematuria resolves within 6 weeks after completing antibiotics in a low-risk patient, no further workup is needed. 2
• Persistent hematuria after infection treatment requires immediate comprehensive urologic evaluation. 2
• In patients >35-40 years or with high-risk features, proceed with full evaluation regardless of concurrent UTI because infection does not exclude malignancy. 2

Hematuria in Anticoagulated Patients

• Do not discontinue warfarin without consulting the prescribing clinician. 3
• Bleeding at therapeutic INR frequently indicates an underlying genitourinary lesion requiring investigation. 3
• For life-threatening hemorrhage, administer vitamin K 10 mg IV with fresh frozen plasma or prothrombin complex concentrate. 3

Pediatric Considerations

• Children with isolated microscopic hematuria without proteinuria or dysmorphic RBCs are unlikely to have clinically significant renal disease and do not require imaging. 2
• Renal ultrasound is the preferred first-line imaging for children with gross hematuria to exclude nephrolithiasis, anatomic abnormalities, and rarely tumors. 2
• CT is not appropriate in the initial evaluation of isolated nonpainful, nontraumatic hematuria in children. 2

Follow-Up Protocol After Negative Initial Evaluation

If the complete workup is negative but hematuria persists: 1, 2, 3

• Repeat urinalysis at 6,12,24, and 36 months with blood pressure monitoring at each visit. 1, 2
• After two consecutive negative annual urinalyses, further testing is unnecessary. 2, 3
• Consider repeat comprehensive evaluation within 3-5 years for persistent hematuria in high-risk patients. 2, 3

Immediate Re-Evaluation Triggers

• Development of gross hematuria 2, 3
• Significant increase in degree of microscopic hematuria 2
• New urologic symptoms (flank pain, irritative voiding) 2
• Development of hypertension, proteinuria, or evidence of glomerular bleeding 2, 3

Treatment Approach

Treatment is directed at the underlying cause identified during evaluation: 6, 7

• Urologic malignancies: Urgent referral for transurethral resection, nephrectomy, or other definitive oncologic management. 2 Diagnostic delays beyond 9 months are associated with worse cancer-specific survival. 2
• Urolithiasis: Medical expulsive therapy for small stones, urologic intervention for obstructing or large stones. 2
• Glomerular disease: Nephrology management with immunosuppression, blood pressure control, or supportive care depending on specific diagnosis. 2, 7
• Urinary tract infection: Appropriate antibiotics based on culture and sensitivity. 2, 4
• Benign prostatic hyperplasia: Alpha-blockers, 5-alpha reductase inhibitors, or surgical intervention. 2

There is no specific treatment to resolve or prevent hematuria itself—resolution occurs with appropriate management of the underlying disorder. 7